ReShape Lifesciences Inc. is a weight-loss and metabolic health-solutions company. The Company offers an integrated portfolio of products and services that manage and treat obesity and metabolic disease. Its Lap-Band System provides minimally invasive, long-term treatment of obesity and is an alternative to more invasive surgical stapling procedures, such as gastric bypass or sleeve gastrectomy. The investigational Diabetes Bloc-Stim Neuromodulation (DBSN) system utilizes a vagus nerve block and stimulation technology platform for the treatment of type II diabetes and metabolic disorders. The Obalon balloon technology is a non-surgical, swallowable, gas-filled intra-gastric balloon that is designed to provide long-lasting weight loss. Its ReShape Calibration tubes are multifunctional devices compared to reusable bougies and disposable gastric tubes. Its Lap-Band 2.0, like the original Lap-Band System, is designed to provide minimally invasive long-term treatment of severe obesity.
Ticker SymbolRSLS
Company nameReShape Lifesciences Inc
IPO dateOct 06, 2016
CEOMr. Paul F. Hickey
Number of employees17
Security typeOrdinary Share
Fiscal year-endOct 06
Address1001 Calle Amanecer
CitySAN CLEMENTE
Stock exchangeNASDAQ Capital Market Consolidated
CountryUnited States of America
Postal code92673
Phone19494296680
Websitehttps://www.reshapelifesciences.com/obalon/
Ticker SymbolRSLS
IPO dateOct 06, 2016
CEOMr. Paul F. Hickey
A total of
0.00
USD has been distributed in dividends over the past 5 years.

No Data